NCT07703436Phase 2Recruiting

Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

Study sponsor: Nuvation Bio Inc. · NUVB

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2030-09Estimated
Enrollment · participants40Estimated
Source updated2026-11-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source